BM 170505

Drug Profile

BM 170505

Latest Information Update: 13 Apr 2007

Price : $50

At a glance

  • Originator Roche
  • Class Antihyperglycaemics
  • Mechanism of Action
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Type 2 diabetes mellitus

Most Recent Events

  • 13 Apr 2007 Discontinued - Preclinical for Type-2 diabetes mellitus in Germany (unspecified route)
  • 10 Jul 1998 No-Development-Reported for Type-2 diabetes mellitus in Germany (Unknown route)
  • 21 Dec 1995 A preclinical study has been added to the pharmacokinetics section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top